Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Lung Cancer Launch To Bolster Roche’s China Sales

This article was originally published in PharmAsia News

Executive Summary

Roche has launched Avastin for lung cancer in China, marking the expanded use of one of the company’s best-selling therapies globally to treat a prevalent cancer type in the country, where new product approvals have been few and far between.

You may also be interested in...



Gene Editing In China: EdiGene Raises Fresh Funds, Aims For First IND

With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.

China Regulatory Express: New Cell Therapy, Gene Editing Guidelines Proposed

Given the high number of such trials in the country, China’s National Medical Products Administration has released separate guidelines for industry on the development of gene and cell therapies and gene editing clinical research. 

China Nears COVID Vaccine Race 'Victory': CNBG

China is nearing the finish line in the coronavirus vaccines race with just “the last kilometer to go”, and its government is already negotiating with the WHO for potential global supplies.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel